New drug cocktail aims to wipe out breast cancer before surgery
Disease control
Not yet recruiting
This phase 2 trial tests whether adding the drug inavolisib to a standard pre-surgery regimen (pertuzumab, trastuzumab, and nab-paclitaxel) can improve outcomes for people with a specific genetic mutation (PIK3CA) in HER2-positive early breast cancer. About 164 participants will …
Phase: PHASE2 • Sponsor: Zhimin Shao • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC